The tissue-based genomic profiling market size is projected to be worth US$ 1.2 billion in 2023. The market is likely to surpass US$ 2.2 billion by 2033 at a CAGR of 6.6% during the forecast period. Due to increasing adoption of tissue based genomics by pharmaceutical and biotechnology companies along with growing clinical research procedures. Tissue-based genetic profiling is rapidly being used by pharmaceutical and biotechnology firms to discover prospective drug targets, plan clinical trials, and create companion diagnostics for their therapeutic products. Incorporating genetic profiling into medication development procedures improves therapy effectiveness and patient stratification.
In both clinical and scientific contexts, tissue-based genomic profiling is used. It aids in the diagnosis and monitoring of illnesses, the selection of relevant medicines, and the tracking of therapy responses in the clinical setting. It aids in the discovery of new biomarkers, the identification of pharmacological targets, and the creation of innovative therapeutic approaches in research.
Other Drivers Propelling the Demand for Tissue-based Genomic Profiling include:
Challenges for Companies /Manufacturers in the Tissue-based Genomic Profiling Market:
Opportunities in the Tissue-based Genomic Profiling Industry:
Latest Trends in the Tissue-based Genomic Profiling Market:
| Attributes | Details |
|---|---|
| Tissue-based Genomic Profiling Market Size (2023) | US$ 1.2 Billion |
| Tissue-based Genomic Profiling Market Projected Size (2033) | US$ 2.2 Billion |
| Value CAGR (2023 to 2033) | 6.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2012 to 2022, the global tissue-based genomic profiling market experienced a CAGR of 5.0%, reaching a market size of US$ 1.2 billion in 2023.
From 2012 to 2022, the global tissue-based genomic profiling industry witnessed steady growth due to the rising technological advancements in the tissue-based genomic profiling. Advances in genomic technology, such as next-generation sequencing (NGS), have fueled the expansion of tissue-based genomic profiling. These technologies have grown more accessible, cost-effective, and capable of analyzing massive volumes of genetic data, allowing for thorough tissue profiling.
Precision medicine, which includes personalizing therapies based on specific patient characteristics, has increased demand for tissue-based genetic profiling. Tissue genomic profiling reveals genetic changes, biomarkers, and therapeutic targets, enabling personalized treatment methods.
Future Forecast for Tissue-based Genomic Profiling Industry:
Looking ahead, the global tissue-based genomic profiling industry is expected to rise at a CAGR of 6.6% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 2.2 billion.
The tissue-based genomic profiling industry is expected to continue its growth trajectory from 2023 to 2033, driven by increasing importance of liquid biopsy. The examination of circulating biomarkers in bodily fluids, known as liquid biopsy, is likely to develop significantly. Liquid biopsy is a non-invasive, real-time monitoring method for illness identification, treatment response evaluation, and minimal residual disease monitoring. Tissue-based genetic profiling will be critical in liquid biopsy diagnosis and personalized therapy decisions.
By allowing the examination of individual cells within a tissue sample, single-cell genomics has the potential to revolutionize tissue-based genetic profiling. This method will provide light on cellular heterogeneity, uncommon cell populations, and clonal development, allowing for a better understanding of disease progression, treatment response, and therapeutic resistance.
| Country | The United States |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 604.5 million |
| CAGR % 2023 to End of Forecast (2033) | 5.7% |
The tissue-based genomic profiling industry in the United States is expected to reach a market value of US$ 604.5 million by 2033, expanding at a CAGR of 5.7%. The growing technological advancements in genomics in the United States can be ascribed to the country's increased market share. Government assistance in the form of financing and regulatory measures is important in driving the industry. Initiatives such as the National Institutes of Health's (NIH) Precision Medicine Initiative and the FDA's regulatory framework for genetic testing have a beneficial influence on the industry.
The United States is a world leader in genomics research, with a well-established infrastructure for genetic profiling. Next-generation sequencing (NGS), molecular diagnostics, and bioinformatics improvements all contribute to the growth of the tissue-based genomic profiling industry.
| Country | The United Kingdom |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 68.9 million |
| CAGR % 2023 to End of Forecast (2033) | 5.8% |
The tissue-based genomic profiling industry in the United Kingdom is expected to reach a market value of US$ 68.9 million, expanding at a CAGR of 5.8% during the forecast period. The National Health Service in the United Kingdom is critical in advancing the use of tissue-based genetic profiling. Initiatives such as Genomics England's 100,000 Genomes Project aim to incorporate genomics into everyday healthcare and personalized treatment, ultimately driving the market.
| Country | China |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 102.1 million |
| CAGR % 2023 to End of Forecast (2033) | 6.4% |
The tissue-based genomic profiling industry in China is anticipated to reach a market value of US$ 102.1 million, moving at a CAGR of 6.4 during the forecast period. The tissue-based genomic profiling industry in China is expected to grow prominently due to the increasing genomics research centers and government support. The Chinese government has made genomes research and precision medicine a priority. Initiatives like the Precision Medicine Initiative and the Healthy China 2030 plan encourage the use of genetic profiling in healthcare, propelling the market.
The Beijing Genomics Institute (BGI) and the Shanghai Genomic Institute are two of China's genomics research institutes. These centers contribute to genomic profiling technology research, development, and innovation, hence supporting market growth.
| Country | Japan |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 144.3 million |
| CAGR % 2023 to End of Forecast (2033) | 6.2% |
The tissue-based genomic profiling industry in Japan is estimated to reach a market value of US$ 144.3 million by 2033, thriving at a CAGR of 6.2%. Japan has made tremendous advances in genomic research, developing low-cost genetic profiling methods. Because of the availability of low-cost sequencing technology and testing services, tissue-based genomic profiling is becoming more accessible to research institutions, fueling market expansion.
| Country | South Korea |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 73.2 Million |
| CAGR % 2023 to End of Forecast (2033) | 6.0% |
The tissue-based genomic profiling industry in South Korea is expected to reach a market value of US$ 73.2 million, expanding at a CAGR of 6.0% during the forecast period. South Korea is a genomics research leader with a well-established genetic profiling infrastructure. Next-generation sequencing (NGS), molecular diagnostics, and bioinformatics improvements all contribute to the growth of the tissue-based genomic profiling industry.
Collaborations between the government, academia, and industry assist genomic profiling technology research, development, and commercialization. Partnerships between the public and private sectors boost innovation and market expansion.
Principal Consultant
The Tumor tissue and liquid DNA profiling is expected to dominate the tissue-based genomic profiling industry with a CAGR of 7.7% from 2023 to 2033. This segment captures a significant market share in 2023 and it is influenced by their unique advantages and applications. Tumor tissue profiling identifies particular genetic abnormalities in cancer cells, assisting in the precise diagnosis and categorization of distinct forms of cancer. Tissue-based genomic profiling can assist cancer patients find the best therapy choices by discovering actionable mutations or biomarkers that can be addressed with particular medicines. Liquid DNA profiling, on the other hand, can reveal genetic anomalies in the early stages of cancer, allowing for early intervention and therapy commencement. These reasons are increasing the market for Tumor tissue and Liquid DNA profiling.
The oncological diagnostics is expected to dominate the tissue-based genomic profiling industry with a CAGR of 6.5% from 2032 to 2033. This segment captures a significant market share in 2023 due to the non-invasive and early detection of cancer.
Genomic profiling has distinct benefits and complements in cancer therapy. Tissue profiling, for example, gives extensive information about the tumor's genetic landscape, whereas liquid DNA profiling provides non-invasive and dynamic monitoring capabilities. The desire for personalized care, improved patient outcomes, and advances in genetic technology are driving demand for both methods. Hence, this applications of genomic profiling in cancer detection, the demand is on the rise for oncological diagnostics over the forecast period.
The diagnostic laboratories are expected to dominate the tissue-based genomic profiling industry with a CAGR of 7.1%% from 2023 to 2033. This segment captures a significant market share in 2023 due to the enhanced accuracy of diagnosis.
Tissue-based genetic profiling enables diagnostic laboratories to provide more precise and personalized diagnostic and treatment recommendations, therefore enhancing patient care and results in a variety of illness areas, including cancer.
The tissue-based genomic profiling industry is highly competitive, with numerous players vying for market share. In such a scenario, key players in the tissue-based genomic profiling industry employ various strategies to stay competitive.
Key Strategies Adopted by the Players
Leading organisations spend in research and development to continuously enhance their genomic profiling technology. They aspire to create more sophisticated platforms, improve sequencing efficiency, data analysis capabilities, and the accuracy and sensitivity of genetic profiling tests. Staying on the cutting edge of technology innovations allows businesses to differentiate themselves and attract clients looking for the most up-to-date and dependable solutions.
Strategic alliances and cooperation with academic institutions, research organisations, and pharmaceutical businesses can increase a company's competitiveness. Collaborations allow major companies to gain access to innovative biomarkers, research findings, and knowledge, allowing them to provide cutting-edge solutions and remain at the forefront of innovation.
Key competitors are concentrating on broadening their market reach by expanding into new geographic regions and developing a strong worldwide presence. They may invest in the establishment of subsidiaries, distribution networks, or strategic partnerships in various countries in order to capitalize on developing market possibilities and obtain a competitive advantage over local competitors.
Key players in the tissue-based genomic profiling industry often engage in mergers and acquisitions to consolidate their market position, expand their product portfolio, and gain access to new markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Tissue-based Genomic Profiling Market:
The growth potential of this market is 6.6% through 2033
China is projected to emerge as a lucrative market.
During 2012 to 2022, the market grew at a CAGR of 5%.
The United States is expected to reach market expansion at a CAGR of 5.7%.
Technological advancement in genomics research drives market growth in Japan.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trend 1.3. Supply Side Trend 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Innovation/Development Trends 4. Value Added Insights 4.1. Product Adoption/Usage Analysis 4.2. Regulatory Scenario 4.3. PESTLE Analysis 4.4. Porter’s Analysis 4.5. Technological Roadmap 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Life Expectancy Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Key Player’s Historic Growth 5.2.2. Increasing Adoption in Drug Discovery and Development 5.2.3. Increase Awareness and Supportive Government Initiatives 5.2.4. Implementation of Numerous Technologies 5.2.5. Significant Investment in Genomics by Government 5.2.6. Advancements in The Field of Gene Therapies 5.2.7. Rising Usage of DNA Sequencing Techniques In The Hospitals 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity 6. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022 6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Technology 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Million) Analysis By Technology, 2012 to 2022 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Technology, 2023 to 2033 7.3.1. Tumor tissue and Liquid DNA profiling 7.3.2. Sequencing Techniques 7.3.2.1. NGS 7.3.2.2. Sanger Sequencing 7.3.2.3. RNA Sequencing 7.3.3. Immunohistochemistry 7.3.4. Others 7.4. Market Attractiveness Analysis By Technology 8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Application 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) By Application, 2012 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033 8.3.1. Personalized Medicine 8.3.2. Oncological Diagnostics 8.3.3. Research 8.3.3.1. Cancer Research 8.3.3.2. Biomarker Discovery 8.3.3.3. Others 8.4. Market Attractiveness Analysis By Application 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) By End User, 2012 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 9.3.1. Research Institutes 9.3.2. Clinical Research Organizations 9.3.3. Hospitals & Clinics 9.3.4. Diagnostic Laboratories 9.3.5. Pharmaceutical & Biotechnology Companies 9.3.6. Others 9.4. Market Attractiveness Analysis By End User 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction 10.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. East Asia 10.3.5. South Asia 10.3.6. Oceania 10.3.7. Middle East and Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 11.1. Introduction 11.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 11.3.1. By Country 11.3.1.1. USA 11.3.1.2. Canada 11.3.2. By Technology 11.3.3. By Application 11.3.4. By End User 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Technology 11.4.3. By Application 11.4.4. By End User 11.5. Market Trends 11.6. Key Market Participants - Intensity Mapping 11.7. Drivers and Restraints - Impact Analysis 11.8. Country Level Analysis & Forecast 11.8.1. USA Market Analysis 11.8.1.1. Introduction 11.8.1.2. Market Analysis and Forecast by Market Taxonomy 11.8.1.2.1. By Technology 11.8.1.2.2. By Application 11.8.1.2.3. By End User 11.8.2. Canada Market Analysis 11.8.2.1. Introduction 11.8.2.2. Market Analysis and Forecast by Market Taxonomy 11.8.2.2.1. By Technology 11.8.2.2.2. By Application 11.8.2.2.3. By End User 12. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. Mexico 12.3.1.2. Brazil 12.3.1.3. Argentina 12.3.1.4. Rest of Latin America 12.3.2. By Technology 12.3.3. By Application 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Technology 12.4.3. By Application 12.4.4. By End User 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. Mexico Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Technology 12.8.1.2.2. By Application 12.8.1.2.3. By End User 12.8.2. Brazil Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Technology 12.8.2.2.2. By Application 12.8.2.2.3. By End User 12.8.3. Argentina Market Analysis 12.8.3.1. Introduction 12.8.3.2. Market Analysis and Forecast by Market Taxonomy 12.8.3.2.1. By Technology 12.8.3.2.2. By Application 12.8.3.2.3. By End User 13. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. UK 13.3.1.2. Germany 13.3.1.3. France 13.3.1.4. Italy 13.3.1.5. Spain 13.3.1.6. BENELUX 13.3.1.7. Russia 13.3.1.8. Rest of Europe 13.3.2. By Technology 13.3.3. By Application 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Technology 13.4.3. By Application 13.4.4. By End User 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. UK Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Technology 13.8.1.2.2. By Application 13.8.1.2.3. By End User 13.8.2. Germany Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Technology 13.8.2.2.2. By Application 13.8.2.2.3. By End User 13.8.3. France Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Technology 13.8.3.2.2. By Application 13.8.3.2.3. By End User 13.8.4. Italy Market Analysis 13.8.4.1. Introduction 13.8.4.2. Market Analysis and Forecast by Market Taxonomy 13.8.4.2.1. By Technology 13.8.4.2.2. By Application 13.8.4.2.3. By End User 13.8.5. Spain Market Analysis 13.8.5.1. Introduction 13.8.5.2. Market Analysis and Forecast by Market Taxonomy 13.8.5.2.1. By Technology 13.8.5.2.2. By Application 13.8.5.2.3. By End User 13.8.6. BENELUX Market Analysis 13.8.6.1. Introduction 13.8.6.2. Market Analysis and Forecast by Market Taxonomy 13.8.6.2.1. By Technology 13.8.6.2.2. By Application 13.8.6.2.3. By End User 13.8.7. Russia Market Analysis 13.8.7.1. Introduction 13.8.7.2. Market Analysis and Forecast by Market Taxonomy 13.8.7.2.1. By Technology 13.8.7.2.2. By Application 13.8.7.2.3. By End User 14. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. China 14.3.1.2. Japan 14.3.1.3. South Korea 14.3.2. By Technology 14.3.3. By Application 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Technology 14.4.3. By Application 14.4.4. By End User 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. China Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Technology 14.8.1.2.2. By Application 14.8.1.2.3. By End User 14.8.2. Japan Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Technology 14.8.2.2.2. By Application 14.8.2.2.3. By End User 14.8.3. South Korea Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Technology 14.8.3.2.2. By Application 14.8.3.2.3. By End User 15. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Malaysia 15.3.1.3. Thailand 15.3.1.4. Indonesia 15.3.1.5. Rest of South Asia 15.3.2. By Technology 15.3.3. By Application 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Technology 15.4.3. By Application 15.4.4. By End User 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. India Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Technology 15.8.1.2.2. By Application 15.8.1.2.3. By End User 15.8.2. Malaysia Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Technology 15.8.2.2.2. By Application 15.8.2.2.3. By End User 15.8.3. Thailand Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Technology 15.8.3.2.2. By Application 15.8.3.2.3. By End User 15.8.4. Indonesia Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Technology 15.8.4.2.2. By Application 15.8.4.2.3. By End User 16. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Australia 16.3.1.2. New Zealand 16.3.2. By Technology 16.3.3. By Application 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Technology 16.4.3. By Application 16.4.4. By End User 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. Australia Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Technology 16.8.1.2.2. By Application 16.8.1.2.3. By End User 16.8.2. New Zealand Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Technology 16.8.2.2.2. By Application 16.8.2.2.3. By End User 17. Middle East and Africa (MEA) Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2012 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. GCC Countries 17.3.1.2. Türkiye 17.3.1.3. South Africa 17.3.1.4. Rest of Middle East and Africa 17.3.2. By Technology 17.3.3. By Application 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Technology 17.4.3. By Application 17.4.4. By End User 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. GCC Countries Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Technology 17.8.1.2.2. By Application 17.8.1.2.3. By End User 17.8.2. Türkiye Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Technology 17.8.2.2.2. By Application 17.8.2.2.3. By End User 17.8.3. South Africa Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Technology 17.8.3.2.2. By Application 17.8.3.2.3. By End User 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Share Analysis of Top Players (%) 18.3. Market Presence Analysis 18.3.1. By Regional Footprint of Players 18.3.2. Product Footprint of Players 18.3.3. Channel Footprint of Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. FOUNDATION MEDICINE, INC. 19.3.1.1. Product Portfolio 19.3.1.2. Key Financials 19.3.1.3. SWOT Analysis 19.3.1.4. Key Developments 19.3.1.5. Sales Footprint 19.3.1.6. Strategy Overview 19.3.1.6.1. Marketing Strategy 19.3.1.6.2. Product Strategy 19.3.1.6.3. Channel Strategy 19.3.2. Laboratory Corporation of America Holdings (Personal Genome Diagnostics Inc. (PGDx) 19.3.2.1. Product Portfolio 19.3.2.2. Key Financials 19.3.2.3. SWOT Analysis 19.3.2.4. Key Developments 19.3.2.5. Sales Footprint 19.3.2.6. Strategy Overview 19.3.2.6.1. Marketing Strategy 19.3.2.6.2. Product Strategy 19.3.2.6.3. Channel Strategy 19.3.3. Illumina, Inc. 19.3.3.1. Product Portfolio 19.3.3.2. Key Financials 19.3.3.3. SWOT Analysis 19.3.3.4. Key Developments 19.3.3.5. Sales Footprint 19.3.3.6. Strategy Overview 19.3.3.6.1. Marketing Strategy 19.3.3.6.2. Product Strategy 19.3.3.6.3. Channel Strategy 19.3.4. QIAGEN 19.3.4.1. Product Portfolio 19.3.4.2. Key Financials 19.3.4.3. SWOT Analysis 19.3.4.4. Key Developments 19.3.4.5. Sales Footprint 19.3.4.6. Strategy Overview 19.3.4.6.1. Marketing Strategy 19.3.4.6.2. Product Strategy 19.3.4.6.3. Channel Strategy 19.3.5. Roche Diagnostics 19.3.5.1. Product Portfolio 19.3.5.2. Key Financials 19.3.5.3. SWOT Analysis 19.3.5.4. Key Developments 19.3.5.5. Sales Footprint 19.3.5.6. Strategy Overview 19.3.5.6.1. Marketing Strategy 19.3.5.6.2. Product Strategy 19.3.5.6.3. Channel Strategy 19.3.6. Thermo Fisher Scientific. 19.3.6.1. Product Portfolio 19.3.6.2. Key Financials 19.3.6.3. SWOT Analysis 19.3.6.4. Key Developments 19.3.6.5. Sales Footprint 19.3.6.6. Strategy Overview 19.3.6.6.1. Marketing Strategy 19.3.6.6.2. Product Strategy 19.3.6.6.3. Channel Strategy 19.3.7. Exact Science 19.3.7.1. Product Portfolio 19.3.7.2. Key Financials 19.3.7.3. SWOT Analysis 19.3.7.4. Key Developments 19.3.7.5. Sales Footprint 19.3.7.6. Strategy Overview 19.3.7.6.1. Marketing Strategy 19.3.7.6.2. Product Strategy 19.3.7.6.3. Channel Strategy 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Tissue-Based Genomic Profiling Market
